Related Experiment Video
Updated: Jan 15, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Machine Learning-Guided Prediction of Formulation Performance in Inhalable Ciprofloxacin-Bile Acid Dispersions with
Tareq Zeyad Bahjat1, Twana Mohammed M Ways2, SadatAbdulla Aziz3,4
1School of Pharmacy, University of Reading, Reading RG6 6AD, U.K.
This study developed ciprofloxacin (CFX) solid dispersions with bile acids for improved dry powder inhaler (DPI) delivery. Chenodeoxycholic acid (CDA) formulations enhanced lung deposition and solubility while maintaining antimicrobial activity.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Respiratory Medicine
Background:
- Ciprofloxacin (CFX) is vital for respiratory infections but faces challenges in dry powder inhaler (DPI) delivery due to poor solubility and high crystallinity.
- Soluble CFX forms risk systemic absorption, compromising targeted lung delivery.
Purpose of the Study:
- To create controlled-release solid dispersions of CFX with primary bile acids (cholic acid - CA, chenodeoxycholic acid - CDA) for enhanced DPI efficacy.
- To improve CFX solubility and lung deposition while retaining antimicrobial activity and assessing safety.
Main Methods:
- Spray drying and ball milling were used to formulate CFX-bile acid solid dispersions.
- Characterization included differential scanning calorimetry, Fourier transform infrared spectroscopy, X-ray diffraction, and dissolution studies.
- Aerodynamic performance was assessed using an Andersen cascade impactor, and antimicrobial activity was tested in vitro.
- In vivo toxicology studies in rats and machine learning models were employed to predict performance and identify critical variables.
Main Results:
- CFX-bile acid dispersions exhibited enhanced solubility and partially amorphous structures.
- Chenodeoxycholic acid (CDA) dispersions showed superior lung deposition (higher fine particle fraction, lower MMAD) and emitted dose compared to cholic acid (CA) dispersions.
- Formulations maintained CFX's antimicrobial efficacy, with mild, dose-dependent hepatic effects observed in vivo, particularly with CDA.
Conclusions:
- Primary bile acid-based solid dispersions offer a promising strategy for developing effective inhalable ciprofloxacin therapies.
- Chenodeoxycholic acid (CDA) demonstrated superior performance for lung deposition and emission in DPI formulations.
- Machine learning effectively predicted formulation performance, identifying key variables like bile acid type and processing parameters.
More Related Videos
04:59Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
Drug Product Performance: In Vitro–In Vivo Correlation
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Bioavailability Enhancement: Drug Solubility Enhancement
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Factors Influencing Drug Absorption: Drug Dissolution